U.S. starts national Medicare coverage policy review for Biogen's Aduhelm

(Reuters) -The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator.

The Centers for Medicare & Medicaid Services (CMS) expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H)

Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older.

Currently, coverage for the drug is determined at the local level by Medicare administrative contractors, who represent 12 jurisdictions across the country.

CMS' coverage decisions are based on an analysis of the benefits of a given therapy to Medicare beneficiaries.

(Reporting by Trisha Roy in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
• Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
• 1789 Capital leads $1 billion Polymarket round at $21 billion valuation - report